Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Neutral Rating by Guggenheim

Key Points

• Guggenheim downgraded Arcturus Therapeutics from a "buy" rating to a "neutral" rating, reflecting a shift in analyst sentiment about the company's stock performance.
• Despite the downgrade, 8 analysts maintain a "buy" rating on the stock, indicating continued interest and support among investors.
• Arcturus Therapeutics reported better-than-expected earnings, with revenue of $28.30 million for the quarter, surpassing analysts' estimates.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was downgraded by Guggenheim from a "buy" rating to a "neutral" rating in a report issued on Wednesday,Briefing.com Automated Import reports.

A number of other research analysts also recently issued reports on the stock. Citigroup reaffirmed a "buy" rating on shares of Arcturus Therapeutics in a research report on Friday, October 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Wells Fargo & Company lowered their target price on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Finally, Zacks Research upgraded shares of Arcturus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.57.

Arcturus Therapeutics Stock Up 7.7%

Shares of Arcturus Therapeutics stock opened at $23.16 on Wednesday. The firm's 50 day moving average price is $19.18 and its 200-day moving average price is $14.74. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $24.17. The company has a market cap of $629.03 million, a P/E ratio of -10.39 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. The firm had revenue of $28.30 million for the quarter, compared to the consensus estimate of $17.64 million. As a group, equities research analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARCT. Diversify Advisory Services LLC acquired a new stake in Arcturus Therapeutics during the 1st quarter valued at approximately $191,000. Y Intercept Hong Kong Ltd acquired a new stake in Arcturus Therapeutics during the 1st quarter valued at approximately $244,000. ARK Investment Management LLC lifted its stake in Arcturus Therapeutics by 3.9% during the 1st quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company's stock valued at $21,270,000 after acquiring an additional 74,629 shares during the period. US Bancorp DE lifted its stake in Arcturus Therapeutics by 218.9% during the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 2,329 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Arcturus Therapeutics during the 1st quarter valued at approximately $161,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.